|
TW201643167A
|
|
Imidazotriazinones as PDE1 inhibitors
|
|
US2016168089A1
|
|
Process for the manufacture of idalopirdine
|
|
GB201518375D0
|
|
Agents,uses and methods
|
|
TW201629064A
|
|
Triazolopyrainones as PDE1 inhibitors
|
|
WO2016046053A1
|
|
Immunological treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
|
|
GB201512216D0
|
|
Agents uses and methods
|
|
GB201512203D0
|
|
Agents,uses and methods
|
|
GB201512211D0
|
|
Agents, uses and methods
|
|
GB201512215D0
|
|
Agents,uses and methods
|
|
GB201512223D0
|
|
Methods for the production and use of high specificity, high affinity antibodies
|
|
DK201500362A1
|
|
Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
|
|
WO2015185499A1
|
|
Pde9 inhibitors with 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbonitrile backbone
|
|
TW201611834A
|
|
Hexahydrofuropyrroles as PDE1 inhibitors
|
|
TW201609713A
|
|
Quinazolin-THF-amines as PDE1 inhibitors
|
|
US2015025081A1
|
|
Phenylimidazole derivatives as PDE10A enzyme inhibitors
|
|
TN2014000288A1
|
|
Pde9 inhibitors with imidazo triazinone backbone
|
|
WO2014170352A1
|
|
Nalmefene for treatment of patients with anxiety disorder
|
|
WO2014170353A1
|
|
Nalmefene for treatment of patients with sleep disorder
|
|
US2016058753A1
|
|
Nalmefene for Treatment of Patients with Mood Disorder
|
|
TW201533043A
|
|
Arylpyrrolopyridine derived compounds as LRRK2 inhibitors
|
